Oren Gilad is President/CEO of Aprea Therapeutics, Inc.. Currently has a direct ownership of 333,395 shares of APRE, which is worth approximately $1.02 Million. The most recent transaction as insider was on Oct 23, 2024, when has been sold 500 shares (Common Stock) at a price of $3.92 per share, resulting in proceeds of $1,960. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 333K
0.57% 3M change
3.29% 12M change
Total Value Held $1.02 Million

Oren Gilad Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 23 2024
BUY
Open market or private purchase
$1,960 $3.92 p/Share
500 Added 0.15%
333,395 Common Stock
Oct 15 2024
BUY
Open market or private purchase
$725 $2.9 p/Share
250 Added 0.08%
332,895 Common Stock
Oct 14 2024
BUY
Open market or private purchase
$2,590 $2.59 p/Share
1,000 Added 0.3%
332,645 Common Stock
Oct 10 2024
BUY
Open market or private purchase
$381 $2.54 p/Share
150 Added 0.05%
331,645 Common Stock
Mar 28 2024
BUY
Grant, award, or other acquisition
-
6,725 Added 1.99%
331,495 Common Stock
Mar 13 2024
BUY
Open market or private purchase
$14,580 $7.29 p/Share
2,000 Added 0.61%
324,770 Common Stock
Mar 09 2023
BUY
Grant, award, or other acquisition
-
4,000 Added 1.22%
322,770 Common Stock
Aug 23 2022
BUY
Conversion of derivative security
-
6,045,100 Added 48.67%
6,375,414 Common Stock
Jul 28 2022
BUY
Grant, award, or other acquisition
-
101,300 Added 23.47%
330,314 Common Stock
OG

Oren Gilad

President/CEO
Boston, MA

Track Institutional and Insider Activities on APRE

Follow Aprea Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Insider Trading

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

News

Receive news related to Aprea Therapeutics, Inc.

Track Activities on APRE